Last reviewed · How we verify
HSK39297 tablets
HSK39297 is an investigational small molecule that modulates specific cellular pathways to treat its target indication.
At a glance
| Generic name | HSK39297 tablets |
|---|---|
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available on HSK39297's precise mechanism of action. As a Phase 3 compound from Haisco Pharmaceutical Group, it is undergoing clinical evaluation, but detailed mechanistic data have not been widely disclosed in accessible literature or regulatory documents.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of HSK39297 in Anti-C5 Treated PNH Patients With Anemia (PHASE3)
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN (PHASE3)
- Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN (PHASE2)
- A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy (PHASE3)
- Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment (PHASE1)
- A Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH） (PHASE2)
- Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PHASE2)
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |